Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir

Virology Journal

Volumn 6, Issue , 2009, Pages

  Gill, Rachel B ^a,c   Frederick, Samuel L ^a   Hartline, Caroll B ^a   Chou, Sunwen ^b   Prichard, Mark N ^a  

^a University of Alabama at Birmingham   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; PROTEIN KINASE; RETINOBLASTOMA PROTEIN; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; GANCICLOVIR KINASE; PHOSPHOTRANSFERASE; RIBONUCLEOSIDE;

ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PROTEIN BINDING; PROTEIN MOTIF; VIRUS RECOMBINANT; VIRUS REPLICATION; CELL CULTURE; CELL LINE; CHEMISTRY; CYTOMEGALOVIRUS; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

HUMAN HERPESVIRUS 5;

AMINO ACID MOTIFS; BENZIMIDAZOLES; CELL LINE; CELLS, CULTURED; CYTOMEGALOVIRUS; ENZYME INHIBITORS; HUMANS; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RETINOBLASTOMA PROTEIN; RIBONUCLEOSIDES; VIRUS REPLICATION;

EID: 60549084602     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-9     Document Type: Article

References (24)

1. Cytomegalovirus (CMV). http://www.cdc.gov/cmv/index.htm
2. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. SB Boppana KB Fowler RF Pass LB Rivera RD Bradford FD Lakeman WJ Britt, J Pediatr 2005 146 817 823 10.1016/j.jpeds.2005.01.059 15973325
3. Congenital cytomegalovirus (CMV) infection and hearing deficit. KB Fowler SB Boppana, J Clin Virol 2006 35 226 231 10.1016/j.jcv.2005.09.016 16386462
4. Antiviral drugs for cytomegalovirus diseases. KK Biron, Antiviral Res 2006 71 154 163 10.1016/j.antiviral.2006.05.002 16765457
5. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. KK Biron RJ Harvey SC Chamberlain SS Good AA Smith 3rd MG Davis CL Talarico WH Miller R Ferris RE Dornsife, Antimicrob Agents Chemother 2002 46 2365 2372 12121906 10.1128/AAC.46.8.2365-2372.2002
6. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. S Chou, Rev Med Virol 2008 18 233 246 10.1002/rmv.574 18383425
7. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. LH Wang RW Peck Y Yin J Allanson R Wiggs MB Wire, Antimicrob Agents Chemother 2003 47 1334 1342 12654667 10.1128/AAC.47.4.1334- 1342.2003
8. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. D Michel I Pavic A Zimmermann E Haupt K Wunderlich M Heuschmid T Mertens, J Virol 1996 70 6340 6346 8709262
9. The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. M van Zeijl J Fairhurst EZ Baum L Sun TR Jones, Virology 1997 231 72 80 10.1006/viro.1997.8523 9143304
10. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. MN Prichard N Gao S Jairath G Mulamba P Krosky DM Coen BO Parker GS Pari, J Virol 1999 73 5663 5670 10364316
11. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. MC Baek PM Krosky Z He DM Coen, J Biol Chem 2002 277 29593 29599 10.1074/jbc.M202312200 12048183
12. Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. JP Kamil DM Coen, J Virol 2007 81 10659 10668 17634236 10.1128/JVI.00497-07
13. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. PM Krosky MC Baek WJ Jahng I Barrera RJ Harvey KK Biron DM Coen PB Sethna, J Virol 2003 77 7720 7727 12829811 10.1128/JVI.77.14.7720-7727.2003
14. Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase. MC Baek PM Krosky A Pearson DM Coen, Virology 2004 324 184 193 10.1016/j.virol.2004.03.015 15183065
15. Cellular elongation factor 1delta is modified in cells infected with representative alpha-, beta-, or gammaherpesviruses. Y Kawaguchi T Matsumura B Roizman K Hirai, J Virol 1999 73 4456 4460 10196346
16. Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. M Marschall A Marzi P aus dem Siepen R Jochmann M Kalmer S Auerochs P Lischka M Leis T Stamminger, J Biol Chem 2005 280 33357 33367 10.1074/jbc.M502672200 15975922
17. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. FM Jault JM Jault F Ruchti EA Fortunato C Clark J Corbeil DD Richman DH Spector, J Virol 1995 69 6697 6704 7474079
18. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. MN Prichard E Sztul SL Daily AL Perry SL Frederick RB Gill CB Hartline DN Streblow SM Varnum RD Smith ER Kern, J Virol 2008 82 5054 5067 18321963 10.1128/JVI.02174-07
19. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. AJ Hume JS Finkel JP Kamil DM Coen MR Culbertson RF Kalejta, Science 2008 320 797 799 10.1126/science.1152095 18467589
20. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. A Felsani AM Mileo MG Paggi, Oncogene 2006 25 5277 5285 10.1038/sj.onc.1209621 16936748
21. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. A Sun L Bagella S Tutton G Romano A Giordano, J Cell Biochem 2007 102 1400 1404 10.1002/jcb.21609 17979151
22. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. S Chou LC Wechel GI Marousek, J Infect Dis 2007 196 91 94 10.1086/518514 17538888
23. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. SL Williams CB Hartline NL Kushner EA Harden DJ Bidanset JC Drach LB Townsend MR Underwood KK Biron ER Kern, Antimicrob Agents Chemother 2003 47 2186 2192 12821466 10.1128/AAC.47.7.2186-2192.2003
24. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. S Chou LC Van Wechel HM Lichy GI Marousek, Antimicrob Agents Chemother 2005 49 2710 2715 15980340 10.1128/AAC.49.7.2710-2715.2005